APJ Receptor Agonists Optimizing Pharmacological Properties
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of small molecule ligands with suitable pharmacological properties for the apelin receptor (APJ), which are essential for therapeutic applications in conditions such as cardiovascular failure, liver fibrosis, cancer, and HIV infection.
Innovation Solution
Development of specific compounds represented by Formula I, which include various substituents and structures, such as adamantanyl, aryl, and heteroaryl groups, designed to act as agonists of the APJ receptor, potentially usable in pharmaceutical compositions for treating various diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule ligands are developed for APJ receptor, then therapeutic applications become feasible, but suitable pharmacological properties are lacking
Solution Approach 1:
The patent systematically varies molecular parameters including substituent types (adamantanyl, aryl, heteroaryl groups), chain lengths, and functional groups to optimize the balance between pharmacological reliability and therapeutic versatility. This involves modifying R1, R2, R3, R4, R5, and R6 substituents to achieve desired receptor binding characteristics while maintaining drug-like properties
Solution Approach 2:
The compounds represent composite molecular structures combining multiple functional moieties (e.g., adamantanyl groups with heteroaryl substituents, or aryl groups with specific chain lengths) to achieve both reliable APJ receptor binding and broad therapeutic applicability across multiple disease states
2Reliability
If various substituent groups are incorporated into compounds, then APJ receptor modulation improves, but molecular complexity increases
Solution Approach 1:
The molecular structure is divided into distinct functional segments: a core structure with systematically varied substituents (R1-R6 positions), allowing each segment to contribute specifically to receptor binding while maintaining overall structural manageability. The substituents include discrete functional groups like adamantanyl, aryl, and heteroaryl that can be independently optimized
Solution Approach 2:
Different regions of the molecule are optimized for specific functions: certain substituent positions are designed for enhanced receptor affinity while others maintain pharmacokinetic properties. The R1, R2, R3, R4, R5, and R6 positions can be independently selected to achieve local optimization of binding interactions without requiring complete structural redesign
Data Source
AI summary
This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.